Cargando…
Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Oral amodiaquine can cause bradycardia, hypotension, and electrocardiograph (ECG...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614325/ https://www.ncbi.nlm.nih.gov/pubmed/36256474 http://dx.doi.org/10.1111/bcp.15569 |
_version_ | 1783605591853236224 |
---|---|
author | Chan, Xin Hui S Chotsiri, Palang Capel, Rebecca A Pike, James Hanboonkunupakarn, Borimas Lee, Sue J Hanafiah, Maryam Win, Yan Naung Cremer, Maegan Kiechel, Jean-René Ogutu, Bernhards Taylor, Walter RJ Burton, Rebecca-Ann B Tarning, Joel White, Nicholas J |
author_facet | Chan, Xin Hui S Chotsiri, Palang Capel, Rebecca A Pike, James Hanboonkunupakarn, Borimas Lee, Sue J Hanafiah, Maryam Win, Yan Naung Cremer, Maegan Kiechel, Jean-René Ogutu, Bernhards Taylor, Walter RJ Burton, Rebecca-Ann B Tarning, Joel White, Nicholas J |
author_sort | Chan, Xin Hui S |
collection | PubMed |
description | BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Oral amodiaquine can cause bradycardia, hypotension, and electrocardiograph (ECG) QT interval prolongation in animals and humans but the relationship of these changes to drug concentrations is not well characterised. METHODS: We conducted a secondary analysis of data from a pharmacokinetic study of the cardiac safety of amodiaquine (10mg/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Non-linear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration-effect relationships for vital sign (pulse rate, blood pressure) and ECG interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. FINDINGS: Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9beats/minute per 100nmol/L), supine systolic blood pressure (1.7mmHg per 100nmol/L), erect systolic blood pressure (1.5mmHg per 100nmol/L), and erect diastolic blood pressure (1.4mmHg per 100nmol/L). The mean QT interval prolongation was 1.4milliseconds per 100nmol/L irrespective of correction factor used after adjustment for residual heart rate dependency. There was no significant independent effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n=7) and desethylamodiaquine (n=8) at 3μmol/litre (amodiaquine: 10% ± 2%; desethylamodiaquine: 12% ± 3%) and 10μmol/litre (amodiaquine: 50% ± 7%; desethylamodiaquine: 46% ± 6%) concentrations with no significant difference in potency between the two compounds. INTERPRETATION: Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarisation. |
format | Online Article Text |
id | pubmed-7614325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-76143252023-03-16 Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies Chan, Xin Hui S Chotsiri, Palang Capel, Rebecca A Pike, James Hanboonkunupakarn, Borimas Lee, Sue J Hanafiah, Maryam Win, Yan Naung Cremer, Maegan Kiechel, Jean-René Ogutu, Bernhards Taylor, Walter RJ Burton, Rebecca-Ann B Tarning, Joel White, Nicholas J Br J Clin Pharmacol Article BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Oral amodiaquine can cause bradycardia, hypotension, and electrocardiograph (ECG) QT interval prolongation in animals and humans but the relationship of these changes to drug concentrations is not well characterised. METHODS: We conducted a secondary analysis of data from a pharmacokinetic study of the cardiac safety of amodiaquine (10mg/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Non-linear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration-effect relationships for vital sign (pulse rate, blood pressure) and ECG interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. FINDINGS: Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9beats/minute per 100nmol/L), supine systolic blood pressure (1.7mmHg per 100nmol/L), erect systolic blood pressure (1.5mmHg per 100nmol/L), and erect diastolic blood pressure (1.4mmHg per 100nmol/L). The mean QT interval prolongation was 1.4milliseconds per 100nmol/L irrespective of correction factor used after adjustment for residual heart rate dependency. There was no significant independent effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n=7) and desethylamodiaquine (n=8) at 3μmol/litre (amodiaquine: 10% ± 2%; desethylamodiaquine: 12% ± 3%) and 10μmol/litre (amodiaquine: 50% ± 7%; desethylamodiaquine: 46% ± 6%) concentrations with no significant difference in potency between the two compounds. INTERPRETATION: Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarisation. 2023-03-01 2022-11-08 /pmc/articles/PMC7614325/ /pubmed/36256474 http://dx.doi.org/10.1111/bcp.15569 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) International license. |
spellingShingle | Article Chan, Xin Hui S Chotsiri, Palang Capel, Rebecca A Pike, James Hanboonkunupakarn, Borimas Lee, Sue J Hanafiah, Maryam Win, Yan Naung Cremer, Maegan Kiechel, Jean-René Ogutu, Bernhards Taylor, Walter RJ Burton, Rebecca-Ann B Tarning, Joel White, Nicholas J Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies |
title | Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies |
title_full | Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies |
title_fullStr | Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies |
title_full_unstemmed | Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies |
title_short | Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies |
title_sort | cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: clinical and pre-clinical studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614325/ https://www.ncbi.nlm.nih.gov/pubmed/36256474 http://dx.doi.org/10.1111/bcp.15569 |
work_keys_str_mv | AT chanxinhuis cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT chotsiripalang cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT capelrebeccaa cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT pikejames cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT hanboonkunupakarnborimas cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT leesuej cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT hanafiahmaryam cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT winyannaung cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT cremermaegan cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT kiecheljeanrene cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT ogutubernhards cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT taylorwalterrj cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT burtonrebeccaannb cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT tarningjoel cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies AT whitenicholasj cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies |